Spotlight On... Recipharm puts up $45M to enhance track-and-trace capabilities; UAE expecting big growth in drug manufacturing; FDA warns about grape suspension agent; and more...

With new rules looming in Europe, contract drugmaker Recipharm intends to invest $45 million (€40 million) over the next three years to improve its drug traceability capabilities for clients. It will invest across its manufacturing network to add new coding and serialization technologies that will enable products to be tagged and traced with identifiable markers that can help thwart counterfeiting. The move comes on the heels of the EU Falsified Medicines Directive, which will require new measures in drug manufacturing starting in 2019. More from FierceCRO

> The United Arab Emirates is taking steps to more than double the number of manufacturing plants over the next 5 years to 34 from 16. Story

> The FDA is warning compounders not to use SyrSpend SF and SyrSpend SF Grape suspending agents in their meds because it is contaminated. Report

> An expert has assured residents of a U.K. township that the process a company intends to use to manufacture cancer drugs containing radioactive ingredients poses no threat to the community. Story

> The pharmaceutical packaging market is forecast to grow to about $7.24 billion by 2020. Release

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.